1887
Rapid communication Open Access
Like 0

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45–74) for one dose only and 89% (95% CI: 79–94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.29.2100670
2021-07-22
2021-09-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.29.2100670
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/29/eurosurv-26-29_4.html?itemId=/content/10.2807/1560-7917.ES.2021.26.29.2100670&mimeType=html&fmt=ahah

References

  1. Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE). I-MOVE-COVID-19 European primary care and hospital networks. I-MOVE. [Accessed: 22 Jun 2021]. Available from: https://www.imoveflu.org/i-move-covid-19/
  2. Epiconcept. COVID-19 vaccine effectiveness at primary care level in Europe: I-MOVE-COVID-19 generic protocol. Paris: Epiconcept. [Accessed: 22 Jun 2021]. Available from: https://www.imoveflu.org/wp-content/uploads/2021/05/I-MOVE-COVID-19-primary-care-COVID-19-vaccine-effectiveness-protocol-v2.3.pdf
  3. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8.  https://doi.org/10.1016/j.vaccine.2013.02.053  PMID: 23499601 
  4. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088):n1088.  https://doi.org/10.1136/bmj.n1088  PMID: 33985964 
  5. Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021;4(6):e2115985.  https://doi.org/10.1001/jamanetworkopen.2021.15985  PMID: 34097044 
  6. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  7. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  8. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21).  https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438  PMID: 34047271 
  9. Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep. 2021;8:871-9.  https://doi.org/10.1016/j.toxrep.2021.04.003  PMID: 33898273 
  10. European Centre for Disease Prevention and Control (ECDC). COVID-19 vaccine rollout overview. Stockholm: ECDC. 2021. Available from: https://covid19-vaccine-report.ecdc.europa.eu/#3_Uptake_of_at_least_one_vaccine_dose_among_adults
  11. Greenwood M, Yule GU. The Statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med. 1915;8(Sect Epidemiol State Med):113-94.  PMID: 19978918 
  12. Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;24:35(36):4796-800.  https://doi.org/10.1016/j.vaccine.2017.07.003 
  13. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA. 2020;324(19):1939-40.  https://doi.org/10.1001/jama.2020.19328  PMID: 33064144 
  14. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccine. 2021 Jun;S0264410X21007076.  https://doi.org/10.1016/j.vaccine.2021.05.099 
/content/10.2807/1560-7917.ES.2021.26.29.2100670
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error